TrialPath

10 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Obesity / overweight

    📍 Arizona Clinical Trials · Chandler, AZ · +22 more US sites · Get directions →

    The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver fat content, when administered in conjunction with reduced-calorie diet and increased physical activity.

    ✓ Study care freePhase 2Ages 18–99Learn more →
  • High blood pressure

    📍 Hospital Paitilla Clinicas y Hospitales · Panama City, · Get directions →

    This study is assess the safety and performance of the Neurotronic Infusion catheter for treatment of patients with Type 2 Diabetes (T2DM) and hypertension.

    ✓ Study care freePhase 1Ages 21–65Learn more →
  • Obesity / overweight

    📍 University of New Mexico Health Sciences Center · Albuquerque, NM · Get directions →

    Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat type 2 diabetes and obesity.

    ✓ Study care freeEarly Phase 1Ages 18–75Learn more →
  • Obesity / overweight

    📍 Cleveland Clinic · Cleveland, OH · Get directions →

    This is a single center randomized double blind controlled study of patients (BMI ≥ 27 kg/m2) with obesity and Atrial Fibrillation (AFIB) randomized to Tirzepatide vs. placebo.

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • Obesity / overweight

    📍 Columbia University Irving Medical Center · New York, NY · Get directions →

    The goal of this study is to learn about how the hormone insulin controls blood sugar. The main question it aims to answer is about how much insulin the body actually needs to maintain a normal blood sugar level.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Obesity / overweight

    📍 Drexel University · Philadelphia, PA · Get directions →

    The proposed study is an open label, non randomized, waitlist controlled single group feasibility study of the feasibility and usability of a digital intervention (called ChangeBite) to be used by individuals with obesity and comorbid binge eating behavior. The proposed research will include approximately 30 participants.

    ✓ Study care freePhase 1Ages 18–70Learn more →
  • Obesity / overweight

    📍 Columbia University Irving Medical Center · New York, NY · Get directions →

    The goal of this study is to learn about how the hormone insulin controls blood sugar in a variety of people. The main question it aims to answer is about how much insulin the body actually needs to maintain a normal blood sugar level.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    📍 University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →

    The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    📍 Columbia University Irving Medical Center · New York, NY · Get directions →

    The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes. The study will use a drug called alpelisib, which interferes with insulin's actions in the body, to answer the study's main question: does the liver continue to respond to insulin's stimulation of fat production even when it loses the ability to stop making glucose (sugar) in response to insulin.

    ✓ Study care freePhase 1Ages 18–70Learn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    📍 Columbia University Irving Medical Center · New York, NY · Get directions →

    The goal of this clinical trial is to compare a one-week course of diazoxide (2 mg/kg per dose x 14 doses) and placebo in people with obesity and insulin resistance (IR) with metabolic dysfunction-associated steatotic liver disease (MASLD). The main question it aims to answer are how mitigation of compensatory hyperinsulinemia with diazoxide affects hepatic de novo lipogenesis, a major contributor to MASLD pathophysiology.

    ✓ Study care freePhase 1Ages 18–65Learn more →